NMPA (China) approves Benlysta to treat active lupus nephritis.- GSK
China’s National Medical Products Administration (NMPA) has granted approval to GlaxoSmithKline’s Benlysta (belimumab) to treat active lupus nephritis (LN) in adults.
The treatment is intended for LN patients who are currently receiving standard of care (SoC). A specific inhibitor of B-lymphocyte stimulator (BLyS), Benlysta is a human monoclonal antibody that attaches to soluble BLyS.
Earlier, Benlysta was approved in China as an add-on treatment in individuals aged five years and above with active systemic lupus erythematosus (SLE). With the latest development, the antibody became the first and only biologic treatment to obtain approval for SLE and LN in the country.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins